手术切除时非典型导管增生升级相关的影像学与病理学特征
这项回顾性分析纳入124例经皮活检证实为ADH并接受手术切除的病例,总体升级率为17.7%(22例),其中17例升级为导管原位癌、5例为浸润性癌。较小的病灶尺寸(p=0.032)和活检时较大的病灶切除百分比(p=0.047)与较低的升级率相关;较大的活检针径(p=0.070)、无坏死(p=0.051)和局灶性ADH(<3个灶,p=0.12)接近与较低升级率相关。作者认为结合这些影像与病理特征进行分层可能有助于识别可考虑替代治疗方案的女性。
要点
- 经皮活检证实的ADH手术切除后总体升级率为17.7%(22/124),其中17例为导管原位癌、5例为浸润性癌。
- 病灶尺寸较小(p=0.032)和活检时病灶切除百分比较大(p=0.047)与较低的升级率相关。
- 较大活检针径(p=0.070)、无坏死(p=0.051)和局灶性ADH(<3个灶,p=0.12)接近与较低升级率相关,被纳入多参数分析。
核心结论
- 对于经皮活检发现ADH的女性,升级风险可能部分取决于病灶大小、活检时病灶切除百分比、坏死是否存在以及ADH的范围;结合这些影像和病理特征对活检证实的ADH患者进行分层,可能有助于识别可考虑替代治疗方案的女性。
研究设计与样本
- 回顾性分析,纳入在本机构接受手术切除的经皮活检证实ADH患者124例,复习活检影像和病理以确定与ADH升级相关的影像学特征(病灶大小、影像学异常、活检类型、针径、针芯数、病灶切除百分比)和病理学特征(组织学钙化、坏死存在、微乳头特征、ADH范围)。
诊断标准与关键数值
- 总体升级率为17.7%(n=22),其中17例升级为导管原位癌、5例升级为浸润性癌。
- 病灶尺寸较小与较低的升级率相关(p=0.032)。
- 活检时病灶切除百分比较大与较低的升级率相关(p=0.047)。
- 较大活检针径(p=0.070)、无坏死(p=0.051)和局灶性ADH(<3个灶,p=0.12)接近与较低升级率相关。
临床应用与阅片要点
- 作者认为,结合病灶大小、活检时病灶切除百分比、坏死存在和ADH范围等影像与病理特征进行分层,可能有助于识别可考虑替代治疗方案的女性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To evaluate radiologic and pathologic features associated with upgrade of atypical ductal hyperplasia (ADH) to ductal carcinoma in situ or invasive breast cancer at surgical excision, in order to identify patients who may consider alternatives to excision.
MATERIALS AND METHODS: This retrospective analysis examined patients who underwent surgical excision of biopsy-proven ADH at our institution. Imaging and pathology from biopsy were reviewed to determine radiologic (lesion size, radiologic abnormality, biopsy type, needle gauge, number of cores, percent of lesion removed) and pathologic features (histologic calcifications, presence of necrosis, micropapillary features, extent of ADH) associated with ADH upgrade.
RESULTS: One hundred twenty four cases of percutaneous biopsy-proven ADH with subsequent excision were included. The overall upgrade rate was 17.7% (n = 22), with 17 cases to ductal carcinoma in situ and five to invasive cancer. Radiologic features associated with a lower upgrade rate were smaller lesion size (p = 0.032) and larger percent of lesion removed at biopsy (p = 0.047). Larger needle gauge at biopsy (p = 0.070), absence of necrosis (p = 0.051) and focal ADH (<3 foci, p = 0.12) were nearly associated with a lower rate of upgrade and were included for the purpose of multi parameter analyses.
CONCLUSION: For women with ADH identified on percutaneous biopsy, the risk of upgrade may in part be determined by lesion size, percent of lesion removed at biopsy, presence of necrosis, and extent of ADH. Using a combination of these radiographic and pathologic features to stratify patients with biopsy-proven ADH may help identify women who could be considered for alternative treatment options.
引用
- Williams KE, Amin A, Hill J, et al. Radiologic and Pathologic Features Associated With Upgrade of Atypical Ductal Hyperplasia at Surgical Excision. Acad Radiol. 2018. PMID: 30318287. doi:10.1016/j.acra.2018.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。